[1] Amyloidosis is the most frequent cause of restrictive cardiomyopathy in the Western world. Unfortunately, this disease is generally misdiagnosed and its natural history and outcomes differ ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

This clearance makes EchoGo ® Amyloidosis the first commercially available software-only medical device to facilitate detection of Cardiac Amyloidosis using echocardiography. Requiring a single ...

Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.

ATTR amyloidosis results from the buildup of ... Both hATTR and ATTRwt increase your risk of cardiomyopathy and heart failure. However, neuropathy (a problem with your nervous system) is a common ...

In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of ...

“We are proud that with this first regulatory submission, we are a significant step closer to bringing vutrisiran to patients with ATTR amyloidosis with cardiomyopathy, which is a steadily ...

an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA, which is currently approved by ...

Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. About ATTR ...

an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved ...